Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.
Sharon M Castellino, Lisa Giulino-Roth, Paul Harker-Murray...
https://pubmed.ncbi.nlm.nih.gov/37505794/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-11-03
1875
Participants Needed
419
Research Sites
N/A
Total Duration
Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.
CONDITIONS
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Brentuximab Vedotin + Nivolumab + ABVD | ABVD Standard Therapy |
|---|---|---|
| What it is | Combination therapy of ABVD chemotherapy plus brentuximab vedotin (CD30-targeted antibody drug conjugate) and nivolumab (PD-1 immune checkpoint inhibitor), given intravenously, with or without ISRT. | ABVD chemotherapy consists of doxorubicin, bleomycin, vinblastine, and dacarbazine, given as standard backbone treatment for limited-stage classical Hodgkin lymphoma. |
| Role in trial | Investigational experimental arm, evaluating added efficacy and safety of brentuximab vedotin plus nivolumab. | Serves as established comparator, representing conventional treatment arm. |
| Primary use | Tested in trial as a novel approach to improve disease-free survival and reduce late effects by adding targeted therapy and immunotherapy to ABVD. | Used as initial curative treatment for children, adolescents, and adults with newly diagnosed limited-stage classical Hodgkin lymphoma. |
| How it is given or performed | Chemotherapy plus brentuximab vedotin and nivolumab administered intravenously, with possible ISRT, following trial protocol combination schedule. | Chemotherapy drugs (doxorubicin, bleomycin, vinblastine, dacarbazine) are given intravenously in cycles per protocol. |
| Evidence status | Efficacy and long-term safety are under investigation in the clinical trial; no published outcome data for this combination in first-line limited-stage disease. | Supported by established guideline evidence as curative backbone for limited-stage classical Hodgkin lymphoma. |
| Important limitations | Potential to reduce late effects with targeted and immunotherapy additions, but long-term safety, impact on infertility, and secondary malignancy risks remain unestablished until trial outcomes are available. | Risks include pulmonary toxicity, infertility, and risk of secondary malignancies. Late effects from bleomycin and alkylating agents are well-documented in pediatric and adult populations. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 8 weeks
Participants receive 2 cycles of ABVD chemotherapy given intravenously on days 1 and 15 of each 28-day cycle.
2 treatment cycles with day 1 and 15 infusions
Duration - Approximately 1 week
Participants undergo PET/CT or MRI scans to assess early response to chemotherapy and determine their risk group and treatment assignment.
1 to 2 imaging visits
Duration - Up to 4 cycles of treatment (about 4 months)
Participants are assigned to one of eight treatment arms based on risk and early response. Treatments include additional chemotherapy cycles, immunotherapy with brentuximab vedotin and nivolumab, and involved-site radiation therapy as applicable.
Regular imaging and blood sample collections during treatment
Duration - Up to 12 years
Participants are monitored every 3 months for the first year, then every 6 months for years 2 and 3, and annually up to 12 years to assess long-term outcomes and side effects.
Regular follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
8
Have more questions? Get in touch with our team for quick support
Sharon M Castellino, Lisa Giulino-Roth, Paul Harker-Murray...
https://pubmed.ncbi.nlm.nih.gov/37505794/National Cancer Institute (NCI)
Lead Sponsor